FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 500 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Fostering Growth and Creativity Through Journaling August 11, 2021 Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... December 7, 2021 Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain April 1, 2022 Load more HOT NEWS New on NCI’s Websites for March 2019 FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... The Winter Solstice What Should People With Cancer Know About Alkaline Water?
